CMS Recommends the Re-opening of U.S. Facilities Under COVID-19

Continue Reading:

Why this News Brief

To understand how the decisions and policies made by the Centers for Medicare and Medicaid Services (CMS) can affect a company's revenue, especially under the current and future COVID-19 environment. To demonstrate this point, this News Brief summarizes key points from a recent CMS recommendation to reverse a prior position to delay elective procedures and surgeries.

*****

On March 18, 2020, CMS recommended the delay of elective medical, surgical and dental procedures and the expansion of surge capacity in selected healthcare settings. The recommendation was made in order to preserve equipment and to free up healthcare workforce to care for patients most need due to the COVID-19 outbreak.

The week of April 20, CMS released recommendations for a Phase 1 re-opening of healthcare facilities to provide non-emergent care for non-COVID-19 patients. Under the Phase 1 recommendations, CMS continues to encourage the application of all telehealth modalities. However, if care cannot be accomplished virtually, recommendations from CMS are now available to guide healthcare systems and facilities to resuming in-person care of non-COVID-19 patients in regions of the U.S. with a low incidence of COVID-19 disease.

The CMS recommendation follows the White House release of a three-phase guideline to re-open the economy and the start of U.S. states issuing orders to slowly begin normalizing their healthcare operations.

Requests for additional information related to the CMS Phase 1 recommendation can be directed to Daniel Zimmerman at d.zimmerman@reimbursement.consulting

About Rowinski Group

Founded in 2004, Rowinski Group LLC is a reimbursement and healthcare payer data analytics consultancy for medical device, digital health, diagnostics and imaging companies. Rowinski Group is based in Silicon Valley – San Francisco bay area with offices at selected client locations.
Rowinski Group has two core service offerings; securing codes and reimbursement on behalf of companies and applying healthcare payer data analytics to help solve companies’ complex business issues such as responding to questions from the FDA and U.S. Payers.
Through these service offerings Rowinski Group helps U.S. and international companies build their U.S. market share for the medical technology they are developing and selling. For more information visit www.reimbursement.consulting

2020.04 v2.03

Continue reading